Journal
JOURNAL OF PHARMACOLOGICAL SCIENCES
Volume 114, Issue 1, Pages 115-118Publisher
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1254/jphs.10064SC
Keywords
angiotensin II-receptor blocker; transporter; uric acid
Categories
Funding
- Japan Society for the Promotion of Science
- Gout Research Foundation of Japan
Ask authors/readers for more resources
Hyperuricemia is currently recognized as a risk factor for cardiovascular diseases. It has been reported that the angiotensin II-receptor blocker (ARB) losartan decreases serum uric acid level. In this study, the effects of another ARB, irbesartan, on [C-14]uric acid-transport activity of renal uric acid reabsorptive transporters URAT1 and URATV1 were examined with Xenopus oocytes expressing each transporter. The results showed that irbesartan (100 - 500 mu M) inhibited the uptake of uric acid via both transporters. The inhibitory effects of irbesartan exceeded those of losartan and other ARBs, and the results suggest that irbesartan can reduce serum uric acid level.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available